Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.
作者信息
Locatelli Franco, Zugmaier Gerhard, Rizzari Carmelo, Morris Joan D, Gruhn Bernd, Klingebiel Thomas, Parasole Rosanna, Linderkamp Christin, Flotho Christian, Petit Arnaud, Micalizzi Concetta, Zeng Yi, Desai Rajendra, Kormany William N, Eckert Cornelia, Möricke Anja, Sartor Mary, Hrusak Ondrej, Peters Christina, Saha Vaskar, Vinti Luciana, von Stackelberg Arend
机构信息
IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy.
Amgen Research (Munich) GmbH, Munich, Germany.
出版信息
Leukemia. 2023 Jan;37(1):222-225. doi: 10.1038/s41375-022-01770-3. Epub 2022 Dec 8.
Abstract
摘要
相似文献
1
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.
Leukemia. 2023 Jan;37(1):222-225. doi: 10.1038/s41375-022-01770-3. Epub 2022 Dec 8.
2
Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Pediatr Blood Cancer. 2022 Aug;69(8):e29715. doi: 10.1002/pbc.29715. Epub 2022 Apr 28.
3
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.
4
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
5
Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission.
Nat Rev Clin Oncol. 2018 Dec;15(12):727-728. doi: 10.1038/s41571-018-0087-y.
6
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
J Immunother Cancer. 2024 Jun 6;12(6):e008213. doi: 10.1136/jitc-2023-008213.
7
High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.
Haematologica. 2022 Sep 1;107(9):2072-2080. doi: 10.3324/haematol.2021.280078.
8
The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
Cancer Med. 2023 Dec;12(24):21978-21984. doi: 10.1002/cam4.6771. Epub 2023 Dec 8.
9
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25.
10
Safety and efficacy of blinatumomab: a real world data.
Ann Hematol. 2020 Apr;99(4):835-838. doi: 10.1007/s00277-019-03854-0. Epub 2020 Feb 20.
引用本文的文献
1
Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia.
Cancer Med. 2025 Aug;14(16):e71159. doi: 10.1002/cam4.71159.
2
Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial.
EClinicalMedicine. 2025 Apr 28;83:103211. doi: 10.1016/j.eclinm.2025.103211. eCollection 2025 May.
3
Blinatumomab use in pediatric B-ALL: where are we now?
Blood Adv. 2025 Aug 12;9(15):3946-3954. doi: 10.1182/bloodadvances.2024014043.
4
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.
Cancers (Basel). 2024 Dec 15;16(24):4181. doi: 10.3390/cancers16244181.
5
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation.
Haematologica. 2025 Mar 1;110(3):596-607. doi: 10.3324/haematol.2024.286350.
6
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.
Front Immunol. 2024 Sep 25;15:1423487. doi: 10.3389/fimmu.2024.1423487. eCollection 2024.
7
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.
Leukemia. 2024 Nov;38(11):2382-2394. doi: 10.1038/s41375-024-02395-4. Epub 2024 Sep 11.
8
Blinatumomab in the Therapy of Acute B-Lymphoid Leukemia.
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024070. doi: 10.4084/MJHID.2024.070. eCollection 2024.
9
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen.
Haematologica. 2025 Jan 1;110(1):234-238. doi: 10.3324/haematol.2024.285837.
10
[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)].
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):629-636. doi: 10.3760/cma.j.cn121090-20240528-00194.
Zotero 插件